Equal purity testing for ranitidine Form 1 and Form 2 are appropriate, judge says.
This article was originally published in The Tan Sheet
GLAXO CALL FOR HIGHER TECHNOLOGY TO PROVE RANITIDINE FORM 2 PURITY REJECTED by federal court Judge Terrence Boyle in a July 5 ruling. Glaxo Wellcome cannot demand that Novopharm use more advanced technology to prove the purity of its Form 1 ranitidine product than that used in Glaxo's original ranitidine patent, the judge stated.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC